Therapeutic options in a patient with highly aggressive multiple sclerosis and genetic predisposition to autoimmune process: a clinical case

T. V. Baidina; Байдина Т. В.; T. N. Trushnikova; Трушникова Т. Н.; I. Yu. Danchenko; Данченко И. Ю.

doi:10.17816/pmj406120-127

Therapeutic options in a patient with highly aggressive multiple sclerosis and genetic predisposition to autoimmune process: a clinical case

Authors: Baidina T.V.¹, Trushnikova T.N.¹, Danchenko I.Y.²
Affiliations:
1. E.A. Vagner Perm State Medical University
2. Perm Regional Clinical Hospital
Issue: Vol 40, No 6 (2023)
Pages: 120-127
Section: Clinical case
URL: https://journals.rcsi.science/PMJ/article/view/254793
DOI: https://doi.org/10.17816/pmj406120-127
ID: 254793

Cite item

Full Text

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

A clinical case of highly aggressive multiple sclerosis in a patient with a family history of demyelinating disease is presented. The effectiveness of early pathogenetic therapy by blocking the adhesion molecules of lymphocytes is demonstrated.

Keywords

highly aggressive multiple sclerosis, demyelination, induction treatment strategy, natalizumab

Full Text

##article.viewOnOriginalSite##

About the authors

T. V. Baidina

E.A. Vagner Perm State Medical University

Author for correspondence.
Email: tatiana_baidina@mail.ru
ORCID iD: 0000-0002-5114-0463

MD, PhD, Professor, Department of Neurology and Medical Genetics

Russian Federation, Perm

T. N. Trushnikova

E.A. Vagner Perm State Medical University

Email: tatiana_baidina@mail.ru
ORCID iD: 0000-0001-9199-7392

Candidate of Medical Sciences, Associate Professor, Department of Neurology and Medical Genetics

Russian Federation, Perm; Perm

I. Yu. Danchenko

Perm Regional Clinical Hospital

Email: tatiana_baidina@mail.ru
ORCID iD: 0000-0002-3145-5409

neurologist

Russian Federation, Perm

References

Rasseyannyj skleroz u vzroslyh i detej: Proekt klinicheskih rekomendacij. 2020, available at: https://mapcms.ru/upload/iblock/a0f/a0f94b14685f83883eb1b7e90bd8cd95.pdf (in Russian).
Kasatkin D.S., Spirin N.N. Rasseyannyj skleroz v fokuse. Prikladnoe rukovodstvo. Moscow: Prakticheskaya medicina 2020 (in Russian).
Díaz C., Zarco L.A., Rivera D.M. Highly active multiple sclerosis: An update. Mult Scler Relat Disord. 2019 May; 30: 215–224. DOI: 10.1016/ j.msard.2019.01.039. Epub 2019. PMID: 30822617.
Arrambide G., Iacobaeus E., Amato M.P., Derfuss T., Vukusic S., Hemmer B., Brundin L., Tintore M. 2018 ECTRIMS Focused Workshop Group. Aggressive multiple sclerosis (2): Treatment. Mult Scler. 2020; 26 (9): 1352458520924595. doi: 10.1177/1352458520924595. Epub ahead of print. PMID: 32530366; PMCID: PMC7412878.
Iacobaeus E., Arrambide G., Amato M.P., Derfuss T., Vukusic S., Hemmer B., Tintore M., Brundin L. 2018 ECTRIMS Focused Workshop Group. Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Mult Scler. 2020; 26 (9): 1352458520925369. DOI: 10.1177/ 1352458520925369. Epub ahead of print. PMID: 32530385; PMCID: PMC7412876.
Bowen J.D. Highly Aggressive Multiple Sclerosis. Continuum (Minneap Minn). 2019; 25 (3): 689–714. doi: 10.1212/CON.0000000000000731. PMID: 31162312.
Davydovskaya M.V., Hachanova N.V., Evdoshenko E.P., Pronin I.N., Bojko A.N., Zaharova M.N., Alifirova V.M., Turova E.A., Malkova N.A., Siverceva S.A., Cukurova L.A., Skoromec A.A., Solodun I.YU. Rekomendacii po algoritmu vybora preparata i planu upravleniya riskami terapii Natalizumabom u pacientov s remittiruyushchim rasseyannym sklerozom. Moscow 2018 (in Russian).
Khoy K., Mariotte D., Defer G., Petit G., Toutirais O., Le Mauff B. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol. 2020; 11: 549842. doi: 10.3389/fimmu.2020.549842. PMID: 33072089; PMCID: PMC7541830.
Khachanova N.V. Vysokoaktivnyĭ rasseiannyĭ skleroz – vozmozhnosti vybora terapii monoklonal'nymi antitelami. Zh Nevrol Psikhiatr Im S.S. Korsakova 2019; 119: 49–57. doi: 10.17116/jnevro20191191049. PMID: 3193498.
Parks N.E., Flanagan E.P., Lucchinetti C.F., Wingerchuk D.M. NEDA treatment target? No evident disease activity as an actionable outcome in practice. J Neurol Sci. 2017; 383: 31–34. doi: 10.1016/j.jns.2017.10.015.
Zheng C., Kar I., Chen C.K., Sau C., Woodson S., Serra A., Abboud H. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs. 2020; 34 (9): 879–896. doi: 10.1007/s40263-020-00756-y. PMID: 32780300; PMCID: PMC7417850.